Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets

IndustryPRwire -- Sonoma Pharmaceuticals announced that it has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn® Technology products into the dental market and has accepted its first order.

Endocyn®, a Microcyn® Technology product manufactured by Sonoma, is a biocompatible root canal irrigant that does not stain teeth or restorations. In a study conducted by the Departments of Endodontics and Cell Biology and Anatomy at Louisiana State University School of Dentistry published in the Journal of Endodontics, Regenerative Endodontics, Endocyn demonstrated less cellular toxicity compared to traditional endodontic irrigants such as sodium hypochlorite. 

Dr. Mark Fontenot, managing member at Gabriel Science, LLC Commented “We believe Endocyn and the Microcyn family of hypochlorous acid products are the next generation of products to help in the management of a myriad of dental, head and neck conditions The Microcyn family of HOCl products is a much needed addition to the treatment options available to dental healthcare providers given Microcyn’s superior performance.”

Amy Trombly, CEO of Sonoma Pharmaceuticals Commented “We are pleased to bring this cutting-edge advance in dental products to the U.S. market and to partner with Gabriel Science, Our proprietary Microcyn technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety. This partnership also furthers Sonoma’s strategy of expanding its offerings of Microcyn-powered products available in the U.S. market.”

Related Posts

Subscribe Our Newsletter